Generate a tailored SOP for Dr. Fuyuhiko Tamanoi. Improve your application with a focused, well-structured draft.
Fuyuhiko Tamanoi's research focuses on signal transduction involving Ras-superfamily G-proteins and nanoparticle-based delivery of anti-cancer drugs. His lab has investigated the function and cellular localization of Ras proteins, which play critical roles in cell growth and differentiation, particularly the novel Ras-superfamily member, Rheb. Genetic studies have demonstrated Rheb's significance in regulating the G1/S transition of the cell cycle and activating the TOR/S6K signaling pathway. His team explores the development of anti-cancer drugs aimed at inhibiting the posttranslational modifications of Ras proteins, such as farnesylation and geranylgeranylation. They have identified small molecular inhibitors known as GGTIs that prevent the proliferation of human cancer cells in vivo and in vitro, showcasing their effectiveness when encapsulated in liposomes for targeted tumor delivery. The lab is also investigating mesoporous silica nanoparticles (MSNs) for controlled release systems in cancer therapy and is exploring methods to use nanovalves for drug delivery, which can be activated by external stimuli.
UCLA Health Jonsson Comprehensive Cancer Center • Los Angeles, CA
Conducts research and teaches in the field of microbiology, immunology, and molecular genetics, focusing on cancer therapy solutions.
Department of Economics admits primarily for the PhD program.